A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

NCT01940887 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

645

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: E10030
DRUG: bevacizumab or aflibercept
DRUG: E10030 sham injection

Sponsor

Ophthotech Corporation